Pages that link to "Q34683786"

The following pages link to A reappraisal of Gaucher disease-diagnosis and disease management algorithms. (Q34683786):

Displaying 46 items.

• Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States (Q26783092) (← links)
• Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease (Q26783393) (← links)
• Understanding the natural history of Gaucher disease (Q26865974) (← links)
• Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation (Q28943547) (← links)
• Neuroimaging of lipid storage disorders (Q30651469) (← links)
• A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia (Q33423295) (← links)
• Hematological manifestations and complications of Gaucher disease (Q33427535) (← links)
• Young-onset dementia (Q33660849) (← links)
• Gaucher disease and its treatment options (Q34386658) (← links)
• Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation (Q35103549) (← links)
• Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity (Q35264738) (← links)
• Gaucher's disease: report of 11 cases with review of literature (Q35605639) (← links)
• Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis (Q36010206) (← links)
• Disease-drug pairs revealed by computational genomic connectivity mapping on GBA1 deficient, Gaucher disease mice (Q36040753) (← links)
• Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment (Q37127644) (← links)
• Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long‐term outcomes of therapy (Q37195824) (← links)
• Role of endosomes and lysosomes in human disease. (Q37718121) (← links)
• Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review (Q38097497) (← links)
• Early diagnosis of Gaucher disease in pediatric patients: proposal for a diagnostic algorithm (Q38240658) (← links)
• Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history (Q38262722) (← links)
• Gaucher disease and bone manifestations (Q38268631) (← links)
• Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians (Q38556823) (← links)
• Case series and literature review of skeletal tumors and their incidence in the Gaucher disease population (Q38814403) (← links)
• Modelling long-term evolution of chitotriosidase in non-neuronopathic Gaucher disease (Q38893633) (← links)
• Successful newborn screening for Gaucher disease using fluorometric assay in China (Q41192668) (← links)
• Pre- and post-testing counseling considerations for the provision of expanded carrier screening: exploration of European geneticists' views (Q41208364) (← links)
• The face of lysosomal storage disorders in India: a need for early diagnosis (Q41720306) (← links)
• Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. (Q41901693) (← links)
• Clinical Utility of Bone Marrow Study in Gaucher Disease: A Case Report of Gaucher Disease Type 3 With Intractable Myoclonic Seizures. (Q43087363) (← links)
• Iron storage in liver, bone marrow and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment (Q47805142) (← links)
• Characterization of variants in the glucosylceramide synthase gene and their association with type 1 Gaucher disease severity. (Q47862820) (← links)
• Tandem mass spectrometry assay of β-glucocerebrosidase activity in dried blood spots eliminates false positives detected in fluorescence assay (Q50178933) (← links)
• Massive Mesenteric Lymphadenopathy Causing Protein-losing Enteropathy in Gaucher Disease (Q51212704) (← links)
• Synonymous Mutations Add a Layer of Complexity in the Diagnosis of Human Osteopetrosis. (Q51610280) (← links)
• A pilot screening of high-risk Gaucher disease children using dried blood spot methods in Shandong province of China. (Q52601965) (← links)
• Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously. (Q54111080) (← links)
• Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Early Diagnosis Consensus (GED-C) Delphi initiative (Q58556601) (← links)
• Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease (Q64043673) (← links)
• Gaucher Disease: New Expanded Classification Emphasizing Neurological Features (Q64226316) (← links)
• The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review. (Q64977522) (← links)
• Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients (Q84511029) (← links)
• Genetic and clinical characteristics of Filipino patients with Gaucher disease (Q90330709) (← links)
• The Importance of a Multidisciplinary Approach in the Management of a Patient with Type I Gaucher Disease (Q90523051) (← links)
• Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy (Q90717467) (← links)
• Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy (Q91909590) (← links)
• Gaucher disease in Montenegro - genotype/phenotype correlations: Five cases report (Q92298753) (← links)